EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE — NOT FDA APPROVED

Thymosin Alpha-1 Dosing Protocol: Clinical Research

Also known as: Tα1, Zadaxin

immunity

Research Reference Only

This information is for educational purposes only. Thymosin Alpha-1 is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Thymosin Alpha-1 is a peptide fragment derived from prothymosin alpha. It has been studied for its immunomodulatory properties and effects on T-cell function.

Mechanisms of Action

Enhances T-cell differentiation
Modulates cytokine production
Supports dendritic cell maturation
Regulates immune response balance

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLink
Immune Enhancement Protocol
clinical trial
1.6 mgTwice weekly6 monthsSubcutaneoushuman

Related Studies

The effect of thymosin alpha 1 on immune response in patients with chronic hepatitis B

human
2007Clinical Immunology
Randomized Controlled Trial

Summary

Thymosin Alpha-1 showed significant improvements in immune markers and viral clearance rates when combined with standard therapy in chronic hepatitis B patients.

Limitations

Specific to hepatitis B population. Requires combination therapy.

View Original Study

Important Warnings

Safety Considerations

  • Prescription drug in some countries
  • Consult healthcare provider